摘要
目的研究辅助内分泌治疗对I期子宫内膜癌患者预后的影响。方法选取1992-01-2002-12共11年间我院诊治I期子宫内膜癌患者105例进行回顾性研究。结果内分泌治疗组和对照组无瘤生存及总生存情况比较,差异无统计学意义(P=0.2639,P=0.2066)。内分泌治疗<12个月及对照组的患者复发/转移10例(14.7%),辅助内分泌治疗≥12个月的患者则为0例,差异有统计学意义(P=0.035);二者因癌死亡患者分别为8例(11.8%)和0例,差异无统计学意义(P=0.074);二者无瘤生存及总生存情况的K-M曲线差异均有统计学意义(P=0.0163,P=0.0396)。多因素分析提示肿瘤细胞分化程度、患者年龄及内分泌治疗时间对I期子宫内膜癌患者的无瘤生存及总存活率有一定影响。结论辅助内分泌治疗12个月或以上,可在一定程度上改善I期子宫内膜癌患者的预后。
Objective To analyze the effects of adjuvant endocrine therapy on the prognosis of stage Ⅰ endometrial carcinoma. Methods A retrospective study was carried out on 105 cases of stage Ⅰ endometrial carcinoma who were admitted to our department from Jan. 1992 to Dec. 2002. The patients were divided into the endocrine therapy group （54 cases, 51.4% ） and the control group （51 cases, 48. 6% ）. Results The rates of recurrence and metastasis in the endocrine therapy group and the control were 5.6% and 13. 7% respectively. And there was no obvious difference on the death from the endometrial carcinoma rate either, which were 3.7% and 11.8% respectively,P = 0. 274, P = 0. 153;so did the survival curve of them（ P =0. 2639, P = 0. 2066 respectively）. The rates of recurrence and metastasis of the control and the patients receiving adjuvant endocrine therapy less than 12 months was 14. 7%. But it was zero for the patients receiving adjuvant endocrine therapy reaching to or longer than 12 months. There was statistical difference between them （P = 0. 035）. The patients died from endometrial carcinoma were 8/68 and 0/37, respectively. There was borderline difference statistically （P =0. 074）. The survival curve of them differed much （P = 0. 0163, P = 0. 0396）. Multivariate analysis showed that the tumor cell differentiation, age and endocrine therapy duration affected the tumor free survival and total survival of stage Ⅰ endometrial carcinoma. Conclusions Adjuvant endocrine therapy no less than 12 months may improve the survival of stage Ⅰ endometrial carcinoma.
出处
《中国实用妇科与产科杂志》
CAS
CSCD
北大核心
2006年第11期824-827,共4页
Chinese Journal of Practical Gynecology and Obstetrics
基金
北京大学211工程循证医学学科群基金(92000-242156011)
"985"工程二期(985-2-015-24)资助
关键词
子宫内膜癌
辅助内分泌治疗
孕激素
预后
Endometrial carcinoma
Adjuvant endocrine therapy
Progesterone
Prognosis
